EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Treatment patterns and Reasons for Discontinuing Preventive Treatment in Cluster Headache: A prospective cohort study

Anja Sofie Petersen iD, Sophie Bryde Laursen iD, Marie-Louise Kulas Søborg iD, Mads Barløse iD, Rigmor Højland Jensen iD, Nunu Lund iD

Cephalalgia · 2026-07 · 46 (7)

DOI: 10.1177/03331024261456265 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cephalalgia, online erschienen am 27.07.2026. Verfasst von Anja Sofie Petersen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Headache Center, University of Copenhagen, Rigshospitalet-Glostrup, Glostrup, Denmark. Hauptthemen laut MEDLINE: Cluster Headache, Verapamil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: H. Lundbeck A/S.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pharmacological prevention of cluster headache aims to reduce the frequency and intensity of attacks, but the long-term effect and tolerance of treatments remain uncertain. The aim of the study was twofold. First, to quantify the discontinuation rates of preventive treatment due to side effects; and second, to assess the proportion of verapamil responders who maintained preventive effectiveness at follow-up .

Methods

In total, 596 participants with cluster headache fulfilling the ICHD-criteria (the baseline cohort) completed a semi-structured interview between 2017 and 2023. Of these, 430 were re-interviewed after a median time of 4.6 years constituting the follow-up cohort.

Results

In the baseline cohort, 457 participants (76.7%) had taken a preventive medicine for cluster headache. Among these, 123 (26.9%) had discontinued a treatment due to intolerable side effects. The discontinuation rate for the first-line treatment verapamil was 18%, whereas the second-line treatments with lithium or topiramate had been discontinued in nearly half. The odds of discontinuing due to intolerable side effects of lithium or topiramate therapy were four times higher than for verapamil (p < 0.0001). In the follow-up cohort, only 143 participants (33.3%) still received a preventive treatment at the time of the second interview. Of the initial 182 verapamil users, 77 (42.3%) continued, 54 (29.7%) had discontinued due to remission, and 51 (28%) discontinued due to intolerable side effects, lack of effect, or for other reasons. At follow-up including new users, a total of 91 participants were treated with verapamil and 50 of them (54.9%) were 50% responders.

Conclusion

Effective therapeutic prevention of cluster headache is hindered by intolerance and insufficient efficacy of the available preventives. Though verapamil remains effective over time for initial responders, there is a high rate of discontinuation due to side effects or lack of efficacy. Taken together with the low proportion of 50% responders, the findings underscore the need for new tolerable and effective preventive treatment for cluster headache.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cluster HeadacheVerapamilHumansFemaleMaleProspective StudiesAdultCohort StudiesMiddle AgedTreatment InterruptionTopiramateCalcium Channel Blockers

Stichwörter der Autor:innen

cluster headachepreventive treatmentside effectsverapamil

Substanzen

VerapamilTopiramateCalcium Channel Blockers

Autor:innen und Institutionen

  • Department of Neurology, Danish Headache Center, University of Copenhagen, Rigshospitalet-Glostrup, Glostrup, Denmark.
  • Department of Clinical Physiology and Nuclear Medicine, Amager and Hvidovre Hospital, Hvidovre, Denmark.
  • Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Anja Sofie Petersen, Sophie Bryde Laursen, Marie-Louise Kulas Søborg, Mads Barløse, Rigmor Højland Jensen, Nunu Lund

Förderung

  • H. Lundbeck A/S

Zitieren

APA

Petersen, A. S., Laursen, S. B., Søborg, M. K., Barløse, M., Jensen, R. H., & Lund, N. (2026). Treatment patterns and Reasons for Discontinuing Preventive Treatment in Cluster Headache: A prospective cohort study. Cephalalgia, 46(7). https://doi.org/10.1177/03331024261456265

Vancouver

Petersen AS, Laursen SB, Søborg MK, Barløse M, Jensen RH, Lund N. Treatment patterns and Reasons for Discontinuing Preventive Treatment in Cluster Headache: A prospective cohort study. Cephalalgia. 2026;46(7). doi:10.1177/03331024261456265

BibTeX
@article{Petersen2026,
  author = {Petersen, Anja Sofie and Laursen, Sophie Bryde and Søborg, Marie-Louise Kulas and Barløse, Mads and Jensen, Rigmor Højland and Lund, Nunu},
  title = {Treatment patterns and Reasons for Discontinuing Preventive Treatment in Cluster Headache: A prospective cohort study},
  journal = {Cephalalgia},
  year = {2026},
  volume = {46},
  number = {7},
  doi = {10.1177/03331024261456265}
}
Kostenlos starten →